| Investigations using albumin binders to modify the tissue distribution profile of radiopharmaceuticals exemplified with folate radioconjugates
Busslinger, S. D., Becker, A. E., Vaccarin, C., Deberle, L. M., Renz, M. L., Groehn, V., … Müller, C. (2023). Investigations using albumin binders to modify the tissue distribution profile of radiopharmaceuticals exemplified with folate radioconjugates. Cancers, 15(17), 4259 (19 pp.). https://doi.org/10.3390/cancers15174259 |
| Design and evaluation of novel albumin-binding folate radioconjugates: systematic approach of varying the linker entities
Benešová, M., Guzik, P., Deberle, L. M., Busslinger, S. D., Landolt, T., Schibli, R., & Müller, C. (2022). Design and evaluation of novel albumin-binding folate radioconjugates: systematic approach of varying the linker entities. Molecular Pharmaceutics, 19, 963-973. https://doi.org/10.1021/acs.molpharmaceut.1c00932 |
| Preclinical investigations to explore the difference between the diastereomers [<sup>177</sup>Lu]Lu-SibuDAB and [<sup>177</sup>Lu]Lu-RibuDAB toward prostate cancer therapy
Borgna, F., Deberle, L. M., Busslinger, S. D., Tschan, V. J., Walde, L. M., Becker, A. E., … Müller, C. (2022). Preclinical investigations to explore the difference between the diastereomers [177Lu]Lu-SibuDAB and [177Lu]Lu-RibuDAB toward prostate cancer therapy. Molecular Pharmaceutics, 19(7), 2105-2114. https://doi.org/10.1021/acs.molpharmaceut.1c00994 |
| [<sup>225</sup>Ac]Ac-SibuDAB for targeted alpha therapy of prostate cancer: preclinical evaluation and comparison with [<sup>225</sup>Ac]Ac-PSMA-617
Busslinger, S. D., Tschan, V. J., Richard, O. K., Talip, Z., Schibli, R., & Müller, C. (2022). [225Ac]Ac-SibuDAB for targeted alpha therapy of prostate cancer: preclinical evaluation and comparison with [225Ac]Ac-PSMA-617. Cancers, 14(22), 5651 (16 pp.). https://doi.org/10.3390/cancers14225651 |
| Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands
Tschan, V. J., Borgna, F., Schibli, R., & Müller, C. (2022). Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands. European Journal of Nuclear Medicine and Molecular Imaging, 49, 470-480. https://doi.org/10.1007/s00259-021-05446-5 |
| Preclinical investigations using [<sup>177</sup>Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer
Tschan, V. J., Borgna, F., Busslinger, S. D., Stirn, M., Monné Rodriguez, J. M., Bernhardt, P., … Müller, C. (2022). Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 49, 3639-3650. https://doi.org/10.1007/s00259-022-05837-2 |
| Combined application of albumin-binding [<sup>177</sup>Lu]Lu-PSMA-ALB-56 and fast-cleared PSMA inhibitors: optimization of the pharmacokinetics
Borgna, F., Deberle, L. M., Cohrs, S., Schibli, R., & Müller, C. (2020). Combined application of albumin-binding [177Lu]Lu-PSMA-ALB-56 and fast-cleared PSMA inhibitors: optimization of the pharmacokinetics. Molecular Pharmaceutics, 17(6), 2044-2053. https://doi.org/10.1021/acs.molpharmaceut.0c00199 |
| Exendin-4 derivatives with an albumin-binding moiety show decreased renal retention and improved GLP-1 receptor targeting
Kaeppeli, S. A. M., Jodal, A., Gotthardt, M., Schibli, R., & Behe, M. (2019). Exendin-4 derivatives with an albumin-binding moiety show decreased renal retention and improved GLP-1 receptor targeting. Molecular Pharmaceutics, 16(9), 3760-3769. https://doi.org/10.1021/acs.molpharmaceut.9b00271 |
| New <sup>55</sup>Co-labeled albumin-binding folate derivatives as potential PET agents for folate receptor imaging
Radford, L. L., Fernandez, S., Beacham, R., Sayed, R. E., Farkas, R., Benešová, M., … Lapi, S. E. (2019). New 55Co-labeled albumin-binding folate derivatives as potential PET agents for folate receptor imaging. Pharmaceuticals, 12(4), 166 (12 pp.). https://doi.org/10.3390/ph12040166 |
| Design and preclinical evaluation of an albumin-binding PSMA ligand for <sup>64</sup>Cu-based PET imaging
Umbricht, C. A., Benešová, M., Hasler, R., Schibli, R., van der Meulen, N. P., & Müller, C. (2018). Design and preclinical evaluation of an albumin-binding PSMA ligand for 64Cu-based PET imaging. Molecular Pharmaceutics, 15(12), 5556-5564. https://doi.org/10.1021/acs.molpharmaceut.8b00712 |
| Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy
Umbricht, C. A., Benešová, M., Schibli, R., & Müller, C. (2018). Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy. Molecular Pharmaceutics, 15(6), 2297-2306. https://doi.org/10.1021/acs.molpharmaceut.8b00152 |
| Folate receptor targeted alpha-therapy using terbium-149
Müller, C., Reber, J., Haller, S., Dorrer, H., Köster, U., Johnston, K., … Schibli, R. (2014). Folate receptor targeted alpha-therapy using terbium-149. Pharmaceuticals, 7(3), 353-365. https://doi.org/10.3390/ph7030353 |
| DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted <sup>177</sup>Lu-radionuclide tumor therapy in mice
Müller, C., Struthers, H., Winiger, C., Zhernosekov, K., & Schibli, R. (2013). DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice. Journal of Nuclear Medicine, 54(1), 124-131. https://doi.org/10.2967/jnumed.112.107235 |
